New drug combo aims to control returning nose cancer
NCT ID NCT07331428
First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial therapy. First, patients receive a targeted drug (MRG003) plus an immunotherapy (tislelizumab) for six weeks. Then they switch to a chemotherapy pill (capecitabine) plus the same immunotherapy for up to a year. The goal is to shrink tumors and keep the cancer from growing. About 25 adults aged 18-70 with locally recurrent cancer (no spread to other organs) will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.